Clinical Trials Logo

Arterial Hypertension clinical trials

View clinical trials related to Arterial Hypertension.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT02709031 Not yet recruiting - Diabetes Clinical Trials

Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium

CHAMP
Start date: June 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes. It is evident from in vitro, animal and human studies that cicletanine's optimal dose in diabetes and other challenging, critically-unmet needs is likely to be higher than that for hypertension. Cicletanine's maximum tolerated dosage is not known, but the drug's dose-limiting effects are documented to be potassium loss and sodium loss from thiazide-type activity (one of the therapeutic mechanisms the drug is known to have); such thiazide-type losses are known to be reversed safely by magnesium. This trial explores the ability of magnesium to enhance cicletanine safety at higher doses in a trial involving patients with hypertension complicated by diabetes.

NCT ID: NCT02483936 Not yet recruiting - Clinical trials for Arterial Hypertension

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Start date: December 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

NCT ID: NCT02087332 Not yet recruiting - Clinical trials for Chronic Heart Failure

Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.

Start date: April 2014
Phase: Phase 4
Study type: Interventional

Study hypothesis is that the time from randomization to the increase of natriuresis (%), time to standardization of natriuresis daily profile, blood pressure profile and the percentage reduction of central hemodynamic parameters will be relatively changed over the study period by more than 15%.

NCT ID: NCT01899027 Not yet recruiting - Clinical trials for Arterial Hypertension

Rosuvastatin for Preventing Complications in Renal Ablation

ARTEMISIA
Start date: January 2014
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to test the hypothesis that twice overnight high-dose rosuvastatin loading before RNA followed by 3-month treatment with regular doses of rosuvastatin can reduce both the acute and late renal artery damage.